Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Early Data Support J&J’s COVID-19 Vaccine Push Into Phase III

Single Dose Promising In Phase I Study

Executive Summary

Johnson & Johnson has released early data putting its COVID-19 vaccine broadly in line with frontrunners from Pfizer and Moderna, but with key advantage of requiring just one injection.

You may also be interested in...



Coronavirus Update: CureVac's EU Vaccine Deal, J&J's New Vaccine Study, BioNTech/Fosun Get China Go-Ahead

CureVac seals EU Deal for 405 million doses of CVnCoV, a second Phase III trial for J&J’s COVID-19 vaccine starts, and BioNTech, Fosun get OK for China vaccine trial.

Coronavirus Update: Lilly To Seek EUA For Olumiant

Hot on the heels of positive news from its monoclonal antibody treatment, Lilly aims to seek emergency authorization for anti-inflammatory treatment Olumiant.

Coronavirus Update: Rapid Restart For AZ’s Vaccine Trial, Pfizer Upsizes Its Phase III

Clearance by UK regulator allows trial to restart, with pivotal US trial hoped to follow suit to keep AstraZeneca and Oxford's candidate on track for a potential late 2020 readout. Plus, new results with Sinovac's vaccine in the elderly and progress with antibodies.

Topics

Related Companies

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel